Biocryst Pharmaceuticals (BCRX) Non Operating Income (2024 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported Non Operating Income for 3 consecutive years, with -$19.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Income rose 18.49% year-over-year to -$19.0 million; the trailing twelve-month figure through Jun 2026 stood at -$68.0 million (up 21.25% YoY), and the FY2025 full-year result was -$73.6 million, up 12.81% from the prior year.
• Non Operating Income advanced to -$19.0 million in Q2 2026 per BCRX's latest filing, from -$19.2 million in the prior quarter.
• Across five years, Non Operating Income topped out at -$12.4 million in Q4 2025 and bottomed at -$23.3 million in Q2 2025.
• Historically, Non Operating Income has averaged -$19.6 million across 3 years, with a median of -$20.5 million in 2024.
• The widest YoY moves for Non Operating Income: up 42.43% in 2025, down 9.58% in 2025.
• Over 3 years, Non Operating Income stood at -$21.5 million in 2024, then surged by 42.43% to -$12.4 million in 2025, then tumbled by 53.55% to -$19.0 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$19.0 million, -$19.2 million, and -$12.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.